Jeffrey Hughes, PA
Medical · Belzoni, MSNPI 1841799616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total.
Across 122 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$940
- AstraZeneca$928
- Boehringer Ingelheim$287
- Lundbeck LLC$215
- Lilly USA, LLC$191
- Johnson & Johnson$165
- plus $684 from 14 others
What the payments were for
- Food & beverage$3,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $940 |
| AstraZeneca | 20 | $928 |
| Boehringer Ingelheim | 11 | $287 |
| Lundbeck LLC | 10 | $215 |
| Lilly USA, LLC | 9 | $191 |
| Johnson & Johnson | 12 | $165 |
| Merck | 6 | $161 |
| GSK | 6 | $112 |
| Abbott | 3 | $58 |
| Bayer | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $48 |
| Amgen | 2 | $41 |
| AbbVie | 2 | $40 |
| Pfizer | 3 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| Novartis | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,410 in reported general payments places this provider in the 70th percentile of 65 medical providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $44,182 |
| JanuviaSitagliptin Phosphate | 57 | $33,437 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $33,418 |
| FarxigaDapagliflozin Propanediol | 54 | $31,264 |
| TradjentaLinagliptin | 51 | $30,644 |
| EliquisApixaban | 52 | $29,994 |
| EntrestoSacubitril/Valsartan | 31 | $22,285 |
| LinzessLinaclotide | 37 | $19,270 |
| JardianceEmpagliflozin | 27 | $16,591 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,179 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,256 |
| XareltoRivaroxaban | 11 | $7,131 |
| MyrbetriqMirabegron | 12 | $7,075 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $7,075 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $6,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $287 | $47,23578 claims |
| Novo NordiskOzempic | $940 | $44,18246 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $928 | $41,52070 claims |
| MerckJanuvia, Janumet Xr | $161 | $40,51273 claims |
| PfizerEliquis | $40 | $29,99452 claims |
| NovartisEntresto | $14 | $22,28531 claims |
| AbbVieLinzess, Synthroid | $40 | $20,35366 claims |
| GSKTrelegy Ellipta | $112 | $15,17922 claims |
| Johnson & JohnsonXarelto | $165 | $7,13111 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $7,07512 claims |
| Sanofi-aventis U.S. LLCLantus | $29 | $1,53211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 65 medical providers in Mississippi.
Other medical in Belzoni
- Shannon YoungerColumbus$63K
- Angela DauroBiloxi$25K
- Jenna HabermanFlowood$14K
- Ashley LarsenOcean Springs$11K
- Elise BuckleyClinton$10K
- Caroline BaldwynMadison$9K
- Miranda SudduthMadison$8K
- Catherine DiazFlowood$7K
- Whitney TrammellMeridian$7K
- Ashley BourgeoisOcean Springs$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.